share_log

RiceBran Technologies (NASDAQ:RIBT) Coverage Initiated at StockNews.com

Defense World ·  Jul 22, 2022 02:51

Stock analysts at StockNews.com began coverage on shares of RiceBran Technologies (NASDAQ:RIBT – Get Rating) in a research report issued on Friday. The firm set a "sell" rating on the stock.

RiceBran Technologies Price Performance

RIBT stock opened at $0.33 on Friday. The stock has a market cap of $17.21 million, a price-to-earnings ratio of -1.51 and a beta of 0.45. RiceBran Technologies has a fifty-two week low of $0.27 and a fifty-two week high of $1.03. The business has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.48. The company has a quick ratio of 1.06, a current ratio of 1.29 and a debt-to-equity ratio of 0.07.

Get RiceBran Technologies alerts:

RiceBran Technologies (NASDAQ:RIBT – Get Rating) last released its earnings results on Thursday, April 28th. The company reported ($0.03) earnings per share (EPS) for the quarter. RiceBran Technologies had a negative net margin of 33.42% and a negative return on equity of 36.82%. The company had revenue of $10.56 million during the quarter.

Insider Activity

In other RiceBran Technologies news, major shareholder Grain Co Continental sold 88,820 shares of the company's stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $0.47, for a total transaction of $41,745.40. Following the completion of the sale, the insider now directly owns 9,117,414 shares in the company, valued at $4,285,184.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,823,554 shares of company stock worth $1,586,160 over the last three months. 3.81% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp bought a new stake in shares of RiceBran Technologies in the 1st quarter worth approximately $69,000. FNY Investment Advisers LLC acquired a new position in shares of RiceBran Technologies during the 2nd quarter valued at $71,000. Finally, Arnhold LLC boosted its stake in shares of RiceBran Technologies by 23.1% during the 1st quarter. Arnhold LLC now owns 240,000 shares of the company's stock worth $108,000 after acquiring an additional 45,000 shares in the last quarter. Hedge funds and other institutional investors own 28.60% of the company's stock.

About RiceBran Technologies

(Get Rating)

RiceBran Technologies, together with its subsidiaries, operates as a specialty ingredient company. It focuses on producing, processing, and marketing of value-added healthy, natural, and nutrient dense products derived from rice and other small grains. The company converts raw rice bran into stabilized rice bran (SRB) and high value derivative products, including RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a nutritious carbohydrate and lipid rich fraction of RiBalance; RiFiber, a protein and fiber rich insoluble derivative of RiBalance; and ProRyza products, which includes derivatives composed of protein and protein/fiber blends.

Featured Articles

  • Get a free copy of the StockNews.com research report on RiceBran Technologies (RIBT)
  • Salesforce Stock is a Resilient Best-of Breed CRM Play
  • How the NYSE and NASDAQ are Different, Why That Matters to Investors
  • Use High Beta Stocks to Maximize Your Investing Profits
  • Stock Market Holidays 2022-2025 – Here's When the NYSE and NASDAQ Will be Closed
  • Why Will Highly-Valued Tesla Move Higher? Results

Receive News & Ratings for RiceBran Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RiceBran Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment